Charles River Laboratories International, Inc. Q3 2025 results
Snapshot
Charles River Laboratories International, Inc. reported $1.00B of revenue in Q3 2025, up -0.5% year over year, with diluted EPS of $1.10 and an operating margin of 13.3%.
- Revenue
- $1.00B
- YoY growth
- +-0.5%
- Diluted EPS
- $1.10
- Operating margin
- 13.3%
What management said
- •During the call, we will primarily discuss non-GAAP financial measures, which we believe help investors gain a meaningful understanding of our core operating results and guidance.
- •The first action is continuing to strengthen our portfolio by investing in core growth initiatives, including through M&A, partnerships, and internal development efforts.
- •We have identified areas of future growth, all of which are well within our core competencies, including opportunities across our three business segments.
- •These actions are expected to result in the sale of certain underperforming or non-core businesses, which will enable us to focus on more profitable growth opportunities.
- •In aggregate, these businesses represent approximately 7% of our estimated 2025 revenue.
- •Once completed, the proposed divestitures are expected to result in non-GAAP earnings accretion of at least $0.30 per share on an annualized basis.
- •As you know, we have taken extensive action with a goal to protect our operating margin and reinvigorate earnings growth.
- •Finally, we remain committed to deploying capital in a disciplined and value-enhancing manner.
- •We will continue to regularly review the optimal balance between strategic acquisitions, stock repurchases, debt repayment, and other uses of capital.
- •As part of our capital allocation strategy, the Board of Directors approved a new $1 billion stock repurchase authorization.
- •Moving on to our quarterly results and demand trends, we are continuing to see clear signs that client demand has stabilized.
- •Before I provide more details on these trends, let me provide highlights of our third quarter performance and updated outlook for the year.
What went well
- •Charles River reported third quarter 2025 revenue of $1 billion, which slightly outperformed the outlook provided in August and led to modest overall outperformance.
- •Non-GAAP earnings per share and revenue modestly exceeded the August outlook, prompting the company to narrow guidance with EPS now expected at the upper end of the prior range at $10.10-$10.30.
- •The company announced strategic review outcomes including a new $1 billion stock repurchase authorization and planned divestitures of underperforming or non-core businesses representing approximately 7% of estimated 2025 revenue, expected to add at least $0.30 of annualized EPS accretion.
- •Management identified approximately $70 million of incremental net annual cost savings on top of $225 million of cumulative annualized savings, for about $100 million of incremental savings in 2026.
- •Free cash flow for the quarter was $178.2 million and the full-year free cash flow outlook was raised to $470 million-$500 million from $430 million-$470 million, while net leverage improved to 2.1 times.
- •DSA proposal activity improved during the quarter, biotech funding showed increasing signs of improvement (October was the second-highest biotech funding month in history), and monthly book-to-bill improved over the prior three to four months.
What went wrong
- •Revenue declined 0.5% year-over-year reported and 1.6% on an organic basis, with declines in both the DSA and manufacturing segments.
- •Revenue for small and mid-sized biotech clients declined, reflecting tighter budgets driven by the softer biotech funding environment in late 2024 and early 2025.
- •DSA net book-to-bill remained in the low 0.8 range for a second consecutive quarter, with a persistent gross and net bookings issue among mid-tier biotech clients.
- •The non-GAAP tax rate rose 700 basis points year-over-year to 28.3%, reflecting the One Big Beautiful Bill Act and global minimum tax provisions.
- •Free cash flow of $178.2 million decreased from a record $213.1 million in the same period last year, driven primarily by lower earnings.
Guidance changes
| Metric | Period | Previous | Current | Change |
|---|---|---|---|---|
| Reported revenue | FY2025 | decline 0.5%-2.5% | decline 0.5%-1.5% | narrowed |
| Organic revenue | FY2025 | decline 1%-3% | decline 1.5%-2.5% | narrowed to middle |
| Non-GAAP EPS | FY2025 | $9.90-$10.30 | $10.10-$10.30 | raised $0.10 at midpoint |
| DSA organic revenue | FY2025 | low to mid-single-digit decline | decline 2.5%-3.5% | improved |
| Manufacturing organic revenue | FY2025 | — | flat to slightly negative | tempered |
| Operating margin | FY2025 | flat to 30 bps decline | flat to 30 bps decline | unchanged |
| Free cash flow | FY2025 | $430M-$470M | $470M-$500M | raised |
| CapEx | FY2025 | — | approximately $200M (~5% of revenue) | lowered |
| Non-GAAP tax rate | FY2025 | 23.5%-24.5% | 23.5%-24.5% | unchanged |
| Net interest expense | FY2025 | $100M-$105M | $100M-$105M | unchanged |
| Reported revenue | Q4 2025 | — | flat to low single-digit decline | new |
| Non-GAAP EPS | Q4 2025 | — | flat to 10% below Q3 level of $2.43 | new |
Performance breakdown
| Metric | YoY change | Reason |
|---|---|---|
| Total revenue | -0.5% reported, -1.6% organic | Declines in DSA and manufacturing partially offset by RMS growth |
| DSA revenue | declined | First-quarter booking strength that drove H1 outperformance returned to recent historical levels |
| Manufacturing revenue | declined | Completion of work for a commercial CDMO client whose Memphis site work wound down in Q2 |
| RMS revenue | increased | Favorable timing of NHP shipments in the quarter |
| Non-GAAP tax rate | +700 bps to 28.3% | Impact of the One Big Beautiful Bill Act and enactment of certain global minimum tax provisions |
| Free cash flow | -$34.9M to $178.2M | Lower earnings, partially offset by sequential working capital improvement |
| Unallocated corporate costs | 5.9% vs 6.6% of revenue | Lower health and fringe-related costs |
Earnings call themes & trends
| Topic | Previous mention | Current period | Trend |
|---|---|---|---|
| DSA demand environment | Stabilizing | Continuing to stabilize; proposals up, cancellations declining | improving |
| Biotech funding | Soft | Improving through Q3; October second-highest month in history | improving |
| Net book-to-bill | 0.82x Q2 | Low 0.8 range, monthly improvement over three to four months | improving |
| Strategic review | Underway | First phase complete; divestitures (~7% of revenue) and cost actions defined | improving |
| Spot pricing | Stable | Stable for a second straight quarter; selective discounting used strategically | stable |
| DSA backlog | ~10 months | ~9 months | stable |
| Capital deployment | $450.7M repurchased since Aug 2024 | New $1B repurchase authorization | improving |
Q&A summary
What are you seeing from customers given back-to-back quarters in the low 0.8 book-to-bill range?
Proposals are up for large pharma and biotech, cancellations are declining, and net bookings are up. There was a slow summer for biotech but strengthening post-summer, with monthly book-to-bill improving for three to four months. Biotech funding was way up in Q3 and October was the second-highest month in history; pharma has finished reducing portfolios and the company is seeing more general tox and early pre-IND work.
Is there a path to DSA growing in 2026?
Management wants to see the year close out, the start of next year, and clients finalizing 2026 budgets (often not until mid or end of Q1) before committing. They want continuing improvement in book-to-bill over a sustained period, alongside the nature of the backlog and study durations, and will watch bookings closely but stopped short of predicting numbers.
Can you double-click on where the incremental $70 million of cost savings is coming from?
The savings come from five categories: network planning/facility consolidation, workforce right-sizing (including G&A), procurement savings, a global business services model just starting, and internal efficiencies/automation. With carryover, this represents about $100 million of incremental savings in 2026, much of which will offset inflationary and cost pressures rather than all dropping to the bottom line.
How would you frame the thought process for DSA growth in 2026?
Management was cautious not to go too deep into 2026 but pointed to big pharma being largely done with restructuring, greater biotech access to capital over the prior four months, book-to-bill improving over three to four months, proposals up, and cancellations down. They are guardedly optimistic but need these factors to continue through Q4 and into Q1 before predicting actual numbers.
Can you elaborate on the higher third-party NHP sourcing costs and whether they will drag on 2026 margins?
Because DSA is meaningfully exceeding the initial mid- to high-single-digit decline outlook, the company had to source from higher-cost third-party NHPs to meet additional expected demand. As long as the company plans consistently with demand levels, it should not be a continuing drag on the business in 2026.
Will you provide color on the targeted divestitures and treat them as discontinued operations?
Management declined to be specific beyond the ~7% of revenue and $0.30 annualized accretion. The company is not yet at the LOI stage but hopes to complete divestitures by the middle of 2026. The businesses do not qualify for discontinued operations under the materiality criteria, so they will remain in continuing operations until divested.